Nevertheless, in our study, we were able to show that patients with HBV DNA levels above 2000 IU/mL, regardless of ALT levels (≥2 × ULN or <2 × ULN), had lower incidence of HCC when they were treated compared to patients who were not treated. This evidence concerns the gene GPT and hepatocellular carcinoma.